Podoplanin, a type I transmembrane protein, is expressed in lymphatic endothelial cells. Although we previously developed an anticanine podoplanin monoclonal antibody (mAb), PMab-38, immunohistochemistry (IHC) showed that it did not react with canine lymphatic endothelial cells. Here, we determined whether PMab-38 recognizes canine podoplanin of squamous cell carcinomas (SCCs) and clarified its epitope. In IHC, PMab-38 reacted with 83% of SCCs (15/18 cases). Flow cytometry showed that the epitope of PMab-38 was different from that of the platelet aggregation-stimulating domain of the N-terminus, which was detected by almost all antipodoplanin mAbs such as D2–40 or NZ-1. PMab-38 is expected to be useful for investigating the function of podoplanin in canine tumors.
Get full access to this article
View all access options for this article.
References
1.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, and TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
2.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
3.
Breiteneder-GeleffS, MatsuiK, SoleimanA, MeranerP, PoczewskiH, KaltR, SchaffnerG, and KerjaschkiD: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol, 1997; 151:1141–1152.
4.
Martin-VillarE, SchollFG, GamalloC, YurritaMM, Munoz-GuerraM, CrucesJ, and QuintanillaM: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer, 2005; 113:899–910.
5.
ZimmerG, KlenkHD, and HerrlerG: Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line. J B Chem, 1995; 270:17815–17822.
6.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
7.
KanekoMK, KunitaA, AbeS, TsujimotoY, FukayamaM, GotoK, SawaY, NishiokaY, and KatoY: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci, 2012; 103:1913–1919.
Ochoa-AlvarezJA, KrishnanH, PastorinoJG, NevelE, KephartD, LeeJJ, RetzbachEP, ShenY, FatahzadehM, BaredesS, KalyoussefE, HonmaM, AdelsonME, KanekoMK, KatoY, YoungMA, Deluca-RaponeL, ShienbaumAJ, YinK, JensenLD, and GoldbergGS: Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget, 2015; 6:9045–9060.
10.
MishimaK, KatoY, KanekoMK, NishikawaR, HiroseT, and MatsutaniM: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl), 2006; 111:483–488.
11.
KatoY, VaidyanathanG, KanekoMK, MishimaK, SrivastavaN, ChandramohanV, PegramC, KeirST, KuanCT, BignerDD, and ZalutskyMR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol, 2010; 37:785–794.
12.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
13.
KatoY, KanekoM, SataM, FujitaN, TsuruoT, and OsawaM: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol, 2005; 26:195–200.
14.
SchoppmannSF, JeschB, RieglerMF, MaroskeF, SchwameisK, JomrichG, and BirnerP: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 2013; 30:441–446.
15.
AbeS, MoritaY, KanekoMK, HanibuchiM, TsujimotoY, GotoH, KakiuchiS, AonoY, HuangJ, SatoS, KishukuM, TaniguchiY, AzumaM, KawazoeK, SekidoY, YanoS, AkiyamaS, SoneS, MinakuchiK, KatoY, and NishiokaY: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol, 2013; 190:6239–6249.
16.
KatoY, SasagawaI, KanekoM, OsawaM, FujitaN, and TsuruoT: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 2004; 23:8552–8556.
HonmaR, KanekoMK, OgasawaraS, FujiiY, KonnaiS, TakagiM, and KatoY: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2016; 35:212–216.
19.
HoshinoA, IshiiG, ItoT, AoyagiK, OhtakiY, NagaiK, SasakiH, and OchiaiA: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res, 2011; 71:4769–4779.
20.
OgasawaraS, KanekoMK, PriceJE, and KatoY: Characterization of anti-podoplanin monoclonal antibodies: Critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma, 2008; 27:259–267.
21.
OkiH, KanekoMK, OgasawaraS, TsujimotoY, LiuX, SugawaraM, TakakuboY, TakagiM, and KatoY: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:174–180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
